How Much Does a Microdose of Tirzepatide Cost?

Short answer, from our own pricing work rather than an estimate: the tirzepatide rate providers lead with runs from about $83 to $599 a month, with a median near $233. That spread is more than thirteen-fold for the same molecule, which tells you the number you pay is set by the seller's pricing structure, not by the drug.

We priced these by hand against each company's own pages and funnels, and the figures move — check the rankings hub for the current per-provider numbers before acting on any of them.

The finding that should change how you shop

There are two pricing structures a low-dose patient cares about, and neither of them wins outright.

"Quoted off the lowest dose" means you pay for what you take, so taking less costs less — but the number you are quoted is a floor. "One price at every dose" means you pay full freight for a quarter dose — but the number never moves.

Run the medians across every provider here with a readable monthly rate and the two structures separate cleanly. Providers that quote off the lowest dose have a median entry rate around $159. Providers that charge one price at every dose have a median entry rate around $175 — dearer to start, and that figure is the whole price rather than a starting point.

So the cheaper opening figure belongs to the structure that charges by the dose, and it stays cheaper only for as long as you stay small. Titrate upward and it climbs toward the flat rate and past it, at a crossover point most sellers will not tell you in advance, because the higher rungs are frequently unpublished. For someone whose plan is genuinely to hold a low dose indefinitely, being charged by the dose is now the better median as well as the better-fitting structure. For anyone expecting to climb, the flat rate is the more predictable buy. We break the structures down in which GLP-1 providers price by dose.

Why the cheap end is cheap

The bottom of the range is not a discount on the same product. It is usually a different product shape:

• •A genuine low-dose SKU sold by the vial, where a small milligram quantity is priced as its own item rather than as a reduced version of a full plan. This is the only structure where taking less mechanically costs less.
• •A membership priced separately from the medication, so the headline is not the bill. A low medication rate beside a monthly membership can total more than a higher all-in figure.
• •A first-month or prepaid rate standing in for the ongoing one. This is the single most common way a published figure misleads, and it is why we record the standing rate rather than the advertised one.

That third pattern is worth stating precisely because it recurs: a rate you can only get by paying a year up front is not a monthly price, and a rate that applies to month one is not what you will pay in month three.

The unit worth checking before the number

A price is a rate over a period, and the period is not always the month it claims. Several providers on this site sell a "month" that is four weeks of medication, which bills thirteen times a year rather than twelve — about 8% more than the annual figure the monthly label implies. One bills every 21 days. Another sells a "three-month" plan that bills every ten weeks.

None of that is hidden; it is written on the same page as the price, in the sentence people skim. When you compare two providers, convert both to an annual figure before deciding which is cheaper, which is what our true cost calculator does.

What the dose does and does not change

Here is the part specific to microdosing. On a flat plan, taking a quarter dose does not reduce the bill at all — the cost per milligram roughly quadruples, which is the arithmetic our flat-rate premium calculator exists to show. On a vial-priced product, a lower dose stretches the vial, so the same purchase covers more weeks and the cost per month genuinely falls.

That distinction — plan versus vial — matters more to your annual spend than the headline rate does, and it is invisible in a price comparison that only reads the number.

What you are buying at any of these prices

Compounded tirzepatide is not FDA-approved, and a microdose sits below the 2.5 mg starting rung the label defines ¹. The efficacy that made the drug famous came from its higher maintenance doses, not its lowest ². And the product carries risks that price comparison cannot see: a pharmacovigilance analysis of compounded GLP-1 receptor agonists found markedly elevated reporting odds for preparation errors, contamination and compounding problems ³, while FDA has documented compounded tirzepatide with false label information, including labels naming compounding pharmacies that do not exist ⁴.

That last point has a pricing consequence people miss: the cheapest vial from an unnamed pharmacy is not the same purchase as a slightly dearer one from a named, verifiable compounder. Provenance is part of the price. The steps are in how to microdose tirzepatide.

The honest bottom line

Budget from the standing rate, converted to a year, from a provider that names its pharmacy. The median tirzepatide figure here sits near $233 a month, the range runs from about $83 to $599, and the difference between those ends is mostly structural rather than clinical. If you intend to hold a low dose long-term, the providers that charge by the dose now carry the cheaper median as well as the better-fitting structure — but their figure is a floor, so find out what the rung above it costs before you assume the saving survives your first titration.

Compare the semaglutide side in what does microdosing GLP-1 cost?, see the structures in full in which GLP-1 providers price by dose, and check the evidence before the invoice in microdosing tirzepatide.